ORB-011 / Orionis - LARVOL DELTA

ORB-011 In Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=55 | Active, not recruiting | Sponsor: Orionis Biosciences Inc | Trial completion date: Dec 2025 ➔ Mar 2026 | Trial primary completion date: Dec 2025 ➔ Mar 2026

Trial completion date • Trial primary completion date • Breast Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer

ORB-011 In Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=55 | Active, not recruiting | Sponsor: Orionis Biosciences Inc | Trial primary completion date: Jun 2025 ➔ Dec 2025

Trial primary completion date • Breast Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer

ORB-011 In Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=55 | Active, not recruiting | Sponsor: Orionis Biosciences Inc | Recruiting ➔ Active, not recruiting | N=36 ➔ 55

Enrollment change • Enrollment closed • Breast Cancer • Head and Neck Cancer • Hormone Receptor Breast Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer

ORB-011 in Patients with Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Orionis Biosciences Inc | Trial completion date: Jun 2025 ➔ Dec 2025 | Trial primary completion date: Mar 2025 ➔ Aug 2025

Trial completion date • Trial primary completion date • Breast Cancer • Head and Neck Cancer • Hormone Receptor Breast Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer

Orionis Biosciences Announces First Patient Dosed in Phase 1 Clinical Trial of ORB-011 in Patients with Advanced Solid Tumors (Businesswire) - "Orionis Biosciences...announced that the first patient has been dosed in a Phase 1 clinical trial of ORB-011, an attenuated, cis-targeted interferon immunotherapy based on the company’s A-Kine platform....ORB-011 is a first-in-class modified interferon designed to act with a high level of precision on cDC1 dendritic immune cells, potent activators of tumor cell killing CD8+ T cells."

Trial status • Solid Tumor

ORB-011 In Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Orionis Biosciences Inc | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Breast Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hormone Receptor Breast Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer

ORB-011 In Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Orionis Biosciences Inc

New P1 trial • Breast Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hormone Receptor Breast Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer